Rob Medcalf Is Working On a Novel Thrombolytic Drug
Monash Translational Medicine shared on LinkedIn:
”Time is brain’ when a person has a stroke.
But even when a patient receives medical attention within 60 minutes, that’s often not enough: tPA, the main drug currently used to treat acute ischemic stroke (the most common stroke type in Australia) isn’t effective for the majority of patients.
Professor Rob Medcalf, of the Australian Centre for Blood Diseases based at Monash Translational Medicine, is working on a novel thrombolytic (clot-busting) drug that could give many more stroke patients a better chance of recovery.
He’s been awarded two Monash University grants – from the Monash Research Impact Fund (MIRF) and the MNHS Commercialisation Incubator Program (MCIP) – to progress development of the drug.
”We desperately need more drug options to treat stroke, for the many patients who can’t go on TPA for reasons ranging from the other medications they’re on, to the short window for effective treatment,” Rob says.
‘These grants will help us address some of the challenges of bringing new drugs to market.”’
-
Oct 2, 2026, 15:37Pall T. Onundarson: Monitoring Warfarin Beyond Factor VII
-
Oct 2, 2026, 15:26Nicola Carter: World Thrombosis Day Highlights Gender Specific Risks and Prevention
-
Oct 2, 2026, 14:56Wolfgang Miesbach: Direct Comparison Reveals Distinct Mechanisms Among FVIIIa Mimetics
-
Oct 2, 2026, 14:47Strengthening Hemophilia Care Through Advocacy and Partnership – World Federation of Hemophilia
-
Oct 2, 2026, 14:40Maxime Dely: CAR T Cell Therapy Starts With Collection
-
Oct 2, 2026, 14:30Sadashiva Pai: The Molecular Gateway for Sphingosine-1-Phosphate Release
-
Oct 2, 2026, 14:17Aditya Rawat: Clopidogrel, CYP2C19 and the Role of Pharmacogenetics
-
Oct 2, 2026, 14:12Monitoring Iron Deficiency in Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Oct 2, 2026, 14:06Giang Tran: Residual Internal Carotid Artery Aneurysm After Flow-Diverter Stenting